Tianjin Lisheng Pharmaceutical Co.,Ltd. (SHE:002393)

SHE:002393 Revenue

Tianjin Lisheng Pharmaceutical had revenue of 246.38M CNY in the quarter ending September 30, 2026, a decrease of -10.66%. This brings the company's total for the last twelve months to 1.27B, down -3.55% year-over-year. In the year 2025, Tianjin Lisheng Pharmaceutical had annual revenue of 1.39B with 4.18% growth. That makes Tianjin Lisheng Pharmaceutical the 17,824th largest company in the world by revenue and 3,246th in China.

• Revenue (ttm): 1.27B
• Revenue Growth: -3.55%
• P/S Ratio: 3.06
• Revenue / Employee: 792.99K
• Employees: 1,605
• Market Cap: 3.83B

Revenue Chart

Chart

Chart

Revenue by Geography

Chart

• Northern China 579.59M 41.6%
• East China 322.92M 23.2%
• South Central China 228.87M 16.4%
• Southwest China 119.22M 8.6%
• North-West China 84.85M 6.1%
• Northeast China 53.88M 3.9%
• Export 2.68M 0.2%

Fiscal year ended Dec 31, 2025 See the full SHE:002393 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.39B	55.86M	4.18%
Dec 31, 2024	1.34B	183.12M	15.88%
Dec 31, 2023	1.15B	6.44M	0.56%
Jan 1, 2023	1.15B	54.65M	5.00%
Jan 1, 2022	1.09B	-48.90M	-4.29%

Data Source: S&P Global Market Intelligence Last updated: Oct 25, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 11, 2026

Data Sources Report a data error